Antibiotic safety assessment

Area of Science:

• Pharmacology and Toxicology
• Drug Safety and Pharmacovigilance
• Medicinal Chemistry

Background:

• Antibiotics generally offer a favorable risk-benefit profile, with adverse effects typically mild and reversible.
• Severe adverse drug reactions (ADRs) to antibiotics, however, can lead to significant morbidity and mortality, necessitating the withdrawal of some drugs.
• The documentation of antibiotic-related ADRs is often insufficient, highlighting a need for improved investigation and prevention strategies.

Purpose of the Study:

• To review current methodologies for investigating and preventing antibiotic-induced toxicity.
• To explore potential future research directions in mitigating antibiotic ADRs.

Main Methods:

• Investigating structure-ADR relationships for various antibiotic classes (e.g., beta-lactams, macrolides, quinolones).
• Examining the role of stereochemical composition, such as enantiomers in quinolones (e.g., ofloxacin), in differential toxicity.
• Considering metabolic variability, genetic differences in drug-metabolizing enzymes, and reactive metabolites as contributors to idiosyncratic toxicity.
• Evaluating the potential of advanced molecular biology techniques, including individual genomic characterization (DNA chip technology), for risk identification.
• Utilizing pharmacokinetic parameters like area under the curve (AUC) and maximum concentration (Cmax) for predicting adverse effects.

Main Results:

• Stereochemical differences, like those between ofloxacin enantiomers, can influence antibiotic toxicity.
• Genetic variations in drug-metabolizing enzymes contribute to population-level differences in ADR risk.
• Chemically reactive metabolites can underlie idiosyncratic antibiotic toxicity.
• Pharmacokinetic parameters show potential for predicting adverse effects.

Conclusions:

• Understanding structure-ADR relationships and metabolic variability is crucial for reducing antibiotic toxicity.
• Genomic characterization holds promise for identifying patients at heightened risk of ADRs.
• Pharmacokinetic profiling can aid in predicting and managing antibiotic-related adverse events.